Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Current Liabilities: 2014-2024

Historic Total Current Liabilities for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $34.1 million.

  • Zevra Therapeutics' Total Current Liabilities fell 24.27% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year decrease of 24.27%. This contributed to the annual value of $34.1 million for FY2024, which is 53.79% down from last year.
  • Per Zevra Therapeutics' latest filing, its Total Current Liabilities stood at $34.1 million for FY2024, which was down 53.79% from $73.7 million recorded in FY2023.
  • Zevra Therapeutics' 5-year Total Current Liabilities high stood at $73.7 million for FY2023, and its period low was $4.2 million during FY2021.
  • For the 3-year period, Zevra Therapeutics' Total Current Liabilities averaged around $39.9 million, with its median value being $34.1 million (2024).
  • As far as peak fluctuations go, Zevra Therapeutics' Total Current Liabilities surged by 513.16% in 2023, and later slumped by 53.79% in 2024.
  • Zevra Therapeutics' Total Current Liabilities (Yearly) stood at $7.5 million in 2020, then tumbled by 43.87% to $4.2 million in 2021, then skyrocketed by 184.23% to $12.0 million in 2022, then soared by 513.16% to $73.7 million in 2023, then tumbled by 53.79% to $34.1 million in 2024.